Med Life SA · BVB:M
Med Life SA — FY2020 Earnings Presentation
17 slides from Med Life SA's earnings presentation, Mar 4, 2021
Slide 1: 2020 Preliminary Financial Results
2020 Preliminary Financial Results Investors and analysts presentation 3-4 March, 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Key messages 12m 2020 Highlights 12m 2020 AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 12m 2020
Highlights 12m 2020 • Key messages 12m 2020 1 4/
Slide 5: Key messages 12m 2020
Key messages 12m 2020 2020 was characterized by rapid switch to the new social and economic context & calibration of the operational structure that helped the company to keep up with the needs of the patients in a pandemic context. - Despite traffic decline in March and April, the group managed to r
Slide 6: Key messages 12m 2020
Key messages 12m 2020 - Beyond financial performance, MedLife managed to play a key role in society and gain detached leadership in pandemic monitoring through active involvement in medical research activities; we plan to intensify these efforts for the longer period and expand the Sars COV 2 virus
Slide 7: Key messages 12m 2020
Key messages 12m 2020 - Reassessment of IFRS 16 standard adoption / change in accounting policy: Management continues to be preoccupied how to adapt to current economic context its contracts under leasing. Given the complexity of IFRS 16, management is constantly looking to improve how to deal with
Slide 8: Key messages 12m 2020
Key messages 12m 2020 - Additional 10.3m RON recognized in Q4 2020 as allowance for receivables Management changed and stressed estimates under IFRS 9 provisioning model to be protected in case of increased probability of default of corporate clients post COVID, anticipating a delay on economical be
Slide 9: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 9/
Slide 10: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 10 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 11: Profit and Loss (1/3) explained
Consolidated Statement of Profit and Loss (1/3) explained 1) 12m 2020 Pro-forma vs. 12m 2019 IFRS ❑ Sales increased by 25.5%, to 1,214m RON ❑ OPEX increased by 20.3%, to 1,104m RON ❑ EBIT more than doubled, to 119.8m RON, leading to 9.9% margin (5.9% in PY), due to improved financial performance and
Slide 12: Profit and Loss (2/3) Operational KPIs
Consolidated Statement of Profit and Loss (2/3) Operational KPIs Sales for 12m 2020 increased by 11.5% vs 12m 2019 (on IFRS) as an effect of: ➢ Acquisitions made and consolidated starting with 1st January 2020 (Micromedica and Lotus); ➢ strong operating performance despite decrease in traffic in Mar
Slide 13: Profit and Loss (3/3) OPEX Evolution
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution Release of 4.2 p.p. in margin due to: ➢ Increase in Consumable & repair materials with 1.3 p.p. of Sales due to reagents and materials related to PCR testing; ➢ Decrease in Rent expenses with 0.5 p.p. of Sales due to renegotiations of re
Slide 14: Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) ➢ Restatement of 2019 IFRS Financial Results due to change in policy in IFRS 16 lead to additional 34.3m RON in Right-of-use asset and 36.3m RON in lease liability for 2019 14 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 15: Financial Position (2/2) Debt position
Consolidated Statement of Financial Position (2/2) Debt position 15 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 16: Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by good operating performance: 1. 17% increase in net cash from operating activities; 2. 2% increase in cash used in investing activities; 3. Increase in cash with 22.6m RON from financing activities 16 / 1.Highlights 2020 2.
Slide 17: Q&A Session Thank you!
Q&A Session Thank you! 3 17 /